Foreign Drug Companies and Japan NHI Market Access Challenges

Japan is the third-largest pharmaceutical market in the world, yet for many foreign drug companies it has become one of the most difficult to enter profitably. That tension — large market, structural barriers — has defined the foreign pharma market access conversation in Japan for years. In 2026, several of those barriers have intensified, while one longstanding irritant has been partially addressed.

The "Drug Lag" Problem Has Not Gone Away

One of Japan's most persistent market access challenges is drug lag — the gap between when a drug is approved in a reference market (typically the US or EU) and when it becomes available to Japanese patients. Drug lag has two components: regulatory lag (time to PMDA approval) and reimbursement lag (time from PMDA approval to NHI listing).

PMDA has invested significantly in parallel scientific advice and international collaboration to reduce regulatory lag, and review timelines for priority products have improved. But the reimbursement side remains slower for foreign companies. The NHI pricing negotiation process requires local clinical data strategies, Japanese-language dossiers, and navigation of Chuikyo's deliberation process — all of which demand Japan-specific infrastructure that many foreign mid-tier companies lack.

Research published in The Lancet and other peer-reviewed journals has documented that low NHI prices and high local clinical trial costs continue to deter foreign pharmaceutical companies from launching in Japan or including Japan in international pivotal trials. When Japan is excluded from multinational trials, PMDA typically requires supplementary bridging studies — adding time and cost, and further extending drug lag.

Annual Price Reductions Create a Profitability Gap

For foreign companies already operating in Japan, the structural shift to annual NHI price revisions since 2021 has meaningfully changed the economics. The FY2026 revision applied an average 4.02% price cut across roughly 15,800 listed products. Compounded annually, these cuts erode margins at a rate that is difficult to offset through volume growth alone in a market with universal insurance coverage and controlled prescribing patterns.

The economics are particularly punishing for drugs that trigger Market Expansion Repricing (MER). When actual NHI expenditure on a product substantially exceeds the forecast used at initial listing, Japan applies additional price cuts. Foreign companies launching innovative drugs — where uptake is often faster than conservative MHLW forecasts — have historically been surprised by MER exposure within two or three years of listing.

The abolition of the MER spillover rule in April 2026 removes one source of indirect exposure, but the core MER mechanism remains. Foreign companies should model MER scenarios explicitly when projecting Japanese revenue beyond year two of launch.

Cost-Effectiveness Assessments: A New Layer of Risk

Japan's cost-effectiveness assessment (CEA) framework has expanded steadily since its introduction in 2019. In FY2026, 49 products underwent CEA review, with 37 receiving additional price reductions averaging approximately 5.3%. For foreign companies with high-priced innovative drugs — the segment most likely to cross CEA threshold expenditure levels — this adds a layer of post-launch price risk that was not present a decade ago.

The CEA framework uses willingness-to-pay thresholds aligned broadly with international HTA norms, but the cost inputs and comparator selection rules in Japan can diverge from submissions made in Europe or Australia. Foreign companies that repurpose European or US HTA dossiers without Japan-specific adaptation frequently find their cost-per-QALY ratios challenged.

The US MFN Rule: An Indirect Pressure

Beginning in 2025, the United States Most-Favored-Nation (MFN) executive order created a new indirect pressure on Japan launch pricing. Under MFN, US drug prices reference international reference prices — including Japan's NHI listed prices. This means foreign companies that launch in Japan at standard NHI prices risk those prices feeding into calculations that reduce their US revenues.

Multiple foreign companies have responded by reconsidering Japan launch timing or seeking early dialogue with MHLW about pricing structures. The MFN dynamic has added a geopolitical dimension to what was previously a purely bilateral market access question.

Pathways That Work for Foreign Companies

Despite these headwinds, foreign companies do launch successfully in Japan. Strategies that tend to work include:

SAKIGAKE designation for drugs with anticipated breakthrough clinical benefit — the 10–20% premium and accelerated review make Japan more commercially viable.
Early PMDA scientific advice to align clinical trial design with Japanese requirements before the global pivotal study begins, avoiding the need for a separate bridging study.
Orphan drug designation for rare disease indications, which provides pricing premiums, extended exclusivity, and a smaller required patient evidence base.
Local partnership with a Japanese pharma company that brings Chuikyo relationships and NHI reimbursement negotiation expertise.

The Japan market rewards deep preparation. Companies that invest in understanding NHI pricing architecture before they reach Chuikyo consistently achieve better outcomes than those navigating it reactively.

NHI Price Wire helps foreign pharma teams monitor Japan's listed price environment across 17,000+ drugs — track competitors, benchmark launch prices, and stay current on annual revision impacts — visit NHI Price Wire.